Company intelligence / Profile preview
Courage Therapeutics
Newton, Massachusetts, United Statescouragetx.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Courage has developed MC4R peptide agonists that demonstrate synergy with GLP1RA drugs for obesity treatment, showing improved efficacy without increased side effects. Their candidates have higher potency and selectivity than setmelanotide with no MC1R activity. They also have first-in-class MC3R peptide agonists with demonstrated activity in CNS to increase feeding behavior in mouse models[8][9].
- Therapeutic areas
- PsychiatryMetabolic DisordersEndocrinologyGeriatricsWomen's HealthOncology
- Modalities
- PeptidesSmall molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Seeking strategic partners with GLP1RA therapeutic programs
Beyond the preview
Go deeper on Courage Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Courage Therapeutics.